Bio-rad Laboratories, Inc. · NYSE:BIO
Bio-rad Laboratories — Q2 2026 Earnings Presentation
18 slides from Bio-rad Laboratories's earnings presentation, Aug 4, 2026
Slide 1: Second Quarter 2026 Financial Results
Second Quarter 2026 Financial Results Supplemental Earnings Results Presentation August 4, 2026
Slide 2: Safe Harbor
Safe Harbor Some statements in this presentation may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding management’s goals, plans, and expectations, our future financial performance, our future
Slide 3: Q2 2026 GAAP Financial Results
Q2 2026 GAAP Financial Results Revenue Gross Operating Net Cash From Margin Margin Operations $651M 53.1% 11.2% $99M Change Flat Flat -60 bps -$18M YoY -1.9% CN* * Currency Neutral Revenue: We report percentage sales growth in currency neutral amounts by calculating translated prior period sales in
Slide 4: Q2 2026 Non-GAAP Financial Results
Q2 2026 Non-GAAP Financial Results Revenue Gross Operating Free Cash Margin* Margin* Flow* $651M 53.9% 12.5% $67M Change Flat +20 bps -110 bps -$4M YoY -1.9% CN** * Reconciliations to the comparable GAAP measure for the non-GAAP items shown above are detailed in the reconciliation table in Bio-Rad’s
Slide 5: Q2 2026 Business Segment Revenue and Geographic Mix
Q2 2026 Business Segment Revenue and Geographic Mix Revenue by Business Revenue by Region Segment APAC 19% EMEA Life Science 35% 39% $651M $651M Clinical Diagnostics 61% Americas 46% 5 Our Mission: Advance Science and Save Lives, Together
Slide 6: Life Science Segment
Life Science Segment Geographic Revenue Mix Q2 2026 Revenue APAC $252M 18% -4.1% YoY EMEA 33% -5.1% YoY CN* • Revenue decreased in the Americas and Asia Pacific, partially offset by increased sales in EMEA.* • Digital PCR instrument revenue increased 20%+, with Americas overall Droplet Digital™ PCR
Slide 7: Clinical Diagnostics Segment
Clinical Diagnostics Segment Geographic Revenue Mix Q2 2026 Revenue APAC $399M 19% +2.6% YoY EMEA +0.3% YoY CN* 37% • Revenue increased in the Americas, partially offset by decreased sales in Asia Pacific.* • Middle East sales grew 7% on channel restocking, amid ongoing market volatility.* Americas
Slide 8: Balance Sheet Highlights
Balance Sheet Highlights (In $ millions) June 30, 2026 December 31, 2025 Cash & Short-Term Investments $1,619 $1,541 Long-Term Debt, including current maturities $1,204 $1,203 Inventories, net $781 $741 Investment in Sartorius AG $4,901 $5,669 8 Our Mission: Advance Science and Save Lives, Together
Slide 9: Full-Year 2026 Outlook
Full-Year 2026 Outlook Range Revenue CN* YoY Growth -3.0% to +0.5% Life Science Revenue CN* YoY -3.0% to -1.0% Clinical Diagnostics Revenue CN* YoY -3.0% to +1.0% Non-GAAP Gross Margin** 53.0% to 54.0% Non-GAAP Operating Margin** 10.0% to 12.0% Free Cash Flow** $290M to $340M * Currency Neutral Reve
Slide 10: Appendix
Appendix
Slide 11: Use of Non-GAAP Financial Measures
Use of Non-GAAP Financial Measures This press release includes GAAP financial measures as well as non-GAAP financial measures, which are not meant to be considered in isolation or as a substitute for comparable GAAP measures. We present certain non-GAAP financial measures to evaluate business perfor
Slide 12: Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures
Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures 12 Our Mission: Advance Science and Save Lives, Together
Slide 13: Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures
Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures 13
Slide 14: Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (continued)
Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (continued) 14 Our Mission: Advance Science and Save Lives, Together
Slide 15: Explanations of Non-GAAP Adjustments
Explanations of Non-GAAP Adjustments Amortization of purchased intangible assets: we do not acquire businesses and assets on a predictable cycle. The amount of purchase price allocated to purchased intangible assets and the terms of amortization can vary significantly and are unique to each acquisit
Slide 16: Other Key Metrics
Other Key Metrics Free Cash Flow: we report free cash flow, which is operating cash flow excluding net capital expenditures, to provide a view of the continuing operations’ ability to generate cash for acquisitions and other investing and financing activities. The company also uses this measure as a
Slide 17: 2026 Financial Outlook
2026 Financial Outlook Forecasted non-GAAP operating margin excludes 89 basis points related to amortization of purchase intangibles. Forecasted non-GAAP operating margin does not reflect future gains and charges that are inherently difficult to predict and estimate due to their unknown timing, effe
Slide 18: Thank You
Thank You